

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate Alzheimer's disease ID6343

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company	General
TauRx Therapeutics	All Wales Therapeutics and Toxicology
(hydromethylthionine mesylate)	Centre
(injurious years)	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Alzheimer's Research UK	Wales
Alzheimer's Society	British National Formulary
Brain and Spine Foundation	Care Quality Commission
Brain Charity	Department of Health, Social Services
Dementia UK	and Public Safety for Northern Ireland
Innovations in Dementia	Healthcare Improvement Scotland
Neurological Alliance	Medicines and Healthcare products
South Asian Health Foundation	Regulatory Agency
Specialised Healthcare Alliance	National Association of Primary Care
Sue Ryder	National Pharmacy Association
,	Neurological Alliance of Scotland
Healthcare professional groups	NHS Confederation
Association of British Neurologists	Scottish Medicines Consortium
Association of Directors of Adult	Wales Neurological Alliance
Social Services	Welsh Government
British Geriatrics Society	Welsh Health Specialised Services
British Neuropathological Society	Committee
British Neuropsychiatry Association	
College of Mental Health Pharmacy	Possible comparator companies
Dementia Action Alliance	Accord Healthcare (donepezil,
National Neuroscience Advisory	memantine)
Group	 Accord-UK (donepezil, galantamine,
Primary Care and Community	memantine)
Neurology Society	Aspire Pharma (galantamine)
Royal College of General Practitioners	Aurobindo Pharma – Milpharm
Royal College of Nursing	(donepezil, galantamine)
Royal College of Pathologists	Cipla (donepezil)
Royal College of Physicians	Dr Reddy's Laboratories (galantamine,
Royal College of Psychiatrists	memantine, rivastigmine)
Royal Pharmaceutical Society	Eisai (donepezil, lecanemab)
Royal Society of Medicine	Eli Lilly and Company (donanemab)

Provisional stakeholder list for the evaluation of hydromethylthionine mesylate for treating Alzheimer's disease ID6343




Consultees	Commentators (no right to submit or
	appeal)
 UK Clinical Pharmacy Association Others Department of Health and Social Care NHS England UCL Dementia Research Centre 	 Fontus Health (galantamine) Genus Pharmaceuticals (memantine) Glenmark Pharmaceuticals (memantine) Kent Pharma (rivastigmine) Krka UK (memantine, rivastigmine) Lundbeck (memantine) Lupin Healthcare (memantine) Mylan (donepezil, memantine, rivastigmine) Novartis Pharmaceuticals (rivastigmine) Ranbaxy, a Sun Pharmaceutical Company (donepezil) Rosemont Pharmaceuticals (donepezil, memantine, rivastigmine) Sandoz (galantamine, rivastigmine) Takeda (galantamine) Thame Laboratories (galantamine) Zentiva (memantine, galantamine)
	Relevant research groups Brain Research UK Cochrane Dementia and Cognitive Improvement Genomics England Institute for Ageing and Health Institute of Neurology MRC Clinical Trials Unit National Hospital for Neurology and Neurosurgery National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Provisional stakeholder list for the evaluation of hydromethylthionine mesylate for treating Alzheimer's disease ID6343



Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.